The EPS estimate of FibroGen, Inc (NASDAQ:FGEN) for quarter ended 2016-09-30 is $-0.5.
EPS projections 7 and 30 days ago were $-0.5 and $-0.5 respectively. Analysts projected $-0.5 and $-0.5 respectively as EPS 60 and 90 days ago. The projections shows a change of 0% from estimates of 7-days ago.
The EPS revisions up and down count in the preceding 7 days were 0 and 0 respectively. The count of bullish revisions in earnings in the last 1-month, 60, 90 and 120 days were 0, 0, 2 and 2.
The count of bearish revisions of EPS in the last 1-month, 60, 90 and 120 days were 0, 0, 1 and 1.
The count of EPS revisions bullish and bearish in the last 18 days were 1 and 1 respectively.
The EPS projection prior to the release of actual report for the period closed 1 is $-0.5 on basis of 3 EPS estimates. As on 2016-05-09, the reported EPS was $-0.45, showing a surprise of $0.24 or 34.78%. It showed a standard deviation of 0.13.
Quarterly Sales Estimates
The arithmetic mean of released annual sales estimates for FibroGen, Inc (NASDAQ:FGEN) is $19.287 and the median is $19.325. The estimate is calculated by 4 analysts for the fiscal 2016.
The highest annual estimate is $24.5 and the lowest estimate is $14. The standard deviation of given annual sales estimates is 4.582%.
As many as 4 and 4 analysts have increased and decreased sales estimate, respectively in last seven days. It shows a percentage change of 0% from the past week.
Almost 4 and 4 analysts have increased and decreased sales estimate, respectively in last one month. It shows a percentage change of 0% from last month.
The number of analysts who have upped and decreased their sales projections in the last one-quarter is 4 and 4 respectively. The change in the estimate from last quarter is -43.005%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...